Page 17 of 29
EN4.18 | Meniere's Disease — SDL Guide (Part 2)
Diagnosis and Differential Diagnosis
The diagnosis of Meniere's disease is clinical and relies on the AAO-HNS (1995) criteria, which are widely used in clinical practice. These criteria require the full clinical picture — both the vestibular and audiological components must be documented. The key diagnostic challenge is that early Meniere's disease may not yet show audiometric evidence of SNHL between attacks, making the 'probable' category important in clinical practice while monitoring for progression. The differential diagnosis of episodic vertigo with audiovestibular symptoms is broader than most students appreciate: BPPV, vestibular neuritis, vestibular migraine, acoustic neuroma, and autoimmune inner ear disease all require consideration, and the history remains the primary tool for distinguishing among them. The table below sets out the diagnostic criteria and the differential.
AAO-HNS (1995) Diagnostic Criteria:
- Definite Meniere's disease: ≥2 spontaneous episodes of vertigo lasting ≥20 minutes each; audiometrically documented low-frequency SNHL; tinnitus or aural fullness; other causes excluded.
- Probable Meniere's disease: ≥1 episode of vertigo; audiometrically documented hearing loss at any frequency; tinnitus or aural fullness.
Differential diagnosis — the most important comparisons:
| Condition | Episode duration | Hearing loss | Tinnitus | Aural fullness | Key distinction |
|---|---|---|---|---|---|
| BPPV | Seconds | No | No | No | Positional; Dix-Hallpike +; no audiovestibular symptoms |
| Vestibular neuritis | Days (single episode) | No | No | No | Single prolonged attack, no hearing symptoms |
| Acoustic neuroma | Variable vertigo | Progressive (not fluctuating) | Unilateral | No | MRI shows CPA/IAC mass |
| Vestibular migraine | Minutes–hours | Variable | Variable | Variable | Migraine headache history; aura; positional component common |
| Autoimmune inner ear disease | Progressive over weeks–months | Bilateral, progressive | Yes | Possible | Responds to steroids; autoimmune markers |
| Syphilitic labyrinthitis | Meniere-like syndrome | Yes | Yes | Yes | Meniere's syndrome; FTA-ABS positive |
Meniere's disease vs vestibular migraine is an increasingly recognised clinical challenge: vestibular migraine is now recognised as the commonest cause of episodic vertigo with audiovestibular symptoms that does not fully meet Meniere's criteria. The key distinguishing features are: personal or family history of migraine headache, photophobia/phonophobia during attacks, and response to antimigraine prophylaxis (amitriptyline, topiramate) rather than Meniere's-specific treatment.
SELF-CHECK
A 55-year-old patient with established Meniere's disease in the right ear has been on maximum medical therapy (low-sodium diet, betahistine, diuretic) for 18 months. She continues to have disabling attacks of vertigo despite treatment. Audiometry shows a pure-tone average of 75 dB on the right side. The most appropriate next step is:
A. Intratympanic methylprednisolone — to reduce attack frequency while preserving hearing
B. Intratympanic gentamicin — chemical labyrinthectomy is appropriate here as hearing is already severely impaired
C. Cochlear implantation for the hearing loss
D. Vestibular rehabilitation therapy as the only evidence-based treatment remaining
Reveal Answer
Answer: B. Intratympanic gentamicin — chemical labyrinthectomy is appropriate here as hearing is already severely impaired
With a PTA of 75 dB (severe SNHL), the hearing on the right side is already severely impaired and the patient has failed maximum medical therapy. Intratympanic gentamicin (chemical labyrinthectomy) ablates the vestibular function of the affected labyrinth and achieves vertigo control in ~85–90% of cases. Since the hearing is already severely impaired (non-serviceable), sacrificing the remaining cochlear function is an acceptable trade-off for vertigo control. Intratympanic methylprednisolone is the preferred option when hearing is still serviceable and preservation is possible — not when it has already reached 75 dB PTA. Cochlear implantation addresses hearing rehabilitation (may be appropriate later) but does not control vertigo. VRT helps compensate for unilateral loss but does not control active Meniere's attacks.
Principles of Management
Management of Meniere's disease follows a step-up approach: begin with the least invasive and least harmful treatments, and escalate if attacks continue to be disabling. The key clinical decision at each step is: is the hearing still serviceable? Hearing preservation strategies are used when the cochlea is still functioning; hearing-sacrificing interventions are reserved for ears where hearing is already severely or profoundly impaired, or the patient accepts hearing loss in exchange for vertigo control. There is no cure for Meniere's disease — all treatments aim to reduce attack frequency and severity, slow disease progression, and manage the residual audiovestibular disability. The step-up approach preserves hearing-restoration options at each stage and avoids irreversible interventions until they are justified by treatment failure.
Step 1 — Lifestyle and dietary modification (first-line, all patients):
- Low-sodium diet (< 1.5–2 g sodium per day): reduces endolymph volume by reducing osmotic load; the foundational non-pharmacological treatment
- Avoid triggers: caffeine, alcohol, nicotine (all increase endolymphatic pressure)
- Stress reduction and regular sleep: attacks can be precipitated by stress and sleep deprivation
Step 2 — Medical therapy:
- Betahistine (8–24 mg three times daily): H3 receptor antagonist and H1 agonist; improves cochlear microcirculation and reduces endolymphatic pressure; standard of care in India and Europe; the BEMED RCT (2016) did not show statistically significant benefit at 9 months but positive open-label evidence supports continued clinical use
- Diuretics (hydrochlorothiazide 25 mg + triamterene, or acetazolamide): reduce endolymph production; used as adjunct to betahistine
- Vestibular suppressants (prochlorperazine, promethazine) during acute attacks for symptomatic relief of vertigo and nausea — NOT for long-term use
Step 3 — Intratympanic therapy (when Steps 1–2 fail):
- Intratympanic dexamethasone/methylprednisolone (IT steroids): hearing-preserving; reduces attack frequency with modest cochlear risk; preferred when hearing is still serviceable; requires repeat injections
- Intratympanic gentamicin (IT-Gent, chemical labyrinthectomy): aminoglycoside selectively destroys vestibular hair cells (cochleotoxicity risk ~10–30% depending on dose); achieves vertigo control in ~85–90% of patients; used when hearing is already severely impaired or patient accepts hearing sacrifice
Step 4 — Surgery (refractory disease):
- Endolymphatic sac decompression (ESD): reduces endolymphatic pressure surgically; hearing-preserving; controversial but performed in select centres
- Vestibular nerve section (neurectomy): selective section of the vestibular branch of VIII; hearing-preserving; provides excellent vertigo control; major intracranial surgery
- Labyrinthectomy: destruction of the entire labyrinth; provides definitive vertigo control; sacrifices all hearing on that side; reserved for non-hearing ears
Hearing rehabilitation: as cochlear damage progresses, conventional hearing aids and ultimately cochlear implantation (for profound bilateral Meniere's disease) are appropriate.
CLINICAL PEARL
The most important clinical fact in Meniere's disease is the episode duration: 20 minutes to several hours — NEVER seconds. An attack lasting only a few seconds is BPPV (or rarely, horizontal canal BPPV). An attack lasting days is vestibular neuritis. Only Meniere's disease produces the combination of hours-duration vertigo with hearing loss, tinnitus, and aural fullness. In any examination clinical station where a patient has 'episodic vertigo', asking specifically 'how long does each attack last?' and then matching to these three ranges (seconds / hours / days) is the single most powerful diagnostic tool. Additionally, the choice between intratympanic steroids and intratympanic gentamicin hinges entirely on the current hearing level: preserving hearing → steroids; hearing already poor → gentamicin.
Self-Assessment: Meniere's Disease
Meniere's disease is the most examination-dense topic in the vestibular cluster because it demands accurate knowledge of all four elements of the tetrad, the precise episode duration that distinguishes it from BPPV and vestibular neuritis, the mechanism of endolymphatic hydrops, the electrocochleographic findings, the AAO-HNS diagnostic criteria, and the step-up management plan including the hearing-related decision point for intratympanic gentamicin versus steroids. The questions below test all of these domains in combination. Before answering, attempt to recall the answer without reference to the SDL; then verify each answer against the relevant section. Particular attention should be paid to the Meniere's vs BPPV distinction and to the intratympanic treatment choice rationale — both are high-frequency viva and OSCE topics.
Key concept checks:
- What are the four features of the Meniere's disease tetrad?
- What is the typical episode duration in Meniere's disease — and how does this differ from BPPV and vestibular neuritis?
- Why does Meniere's disease cause low-frequency SNHL rather than high-frequency?
- What is the SP/AP ratio in electrocochleography, and what does an elevated ratio indicate?
- What is the difference between intratympanic gentamicin and intratympanic steroids, and when is each preferred?
- What is the glycerol dehydration test and what does a positive result imply?
- Distinguish Meniere's disease from Meniere's syndrome.
SELF-CHECK
In Meniere's disease, hearing loss initially affects which frequency range, and why?
A. High frequencies (4000–8000 Hz), because the basal cochlea has the poorest blood supply
B. Low frequencies (250–1000 Hz), because the apical cochlea is most vulnerable to the increased endolymphatic pressure from hydrops
C. Mid-frequencies (1000–2000 Hz), because the middle cochlea is widest and most exposed to pressure changes
D. All frequencies equally, because endolymphatic hydrops affects the entire cochlea uniformly from the start
Reveal Answer
Answer: B. Low frequencies (250–1000 Hz), because the apical cochlea is most vulnerable to the increased endolymphatic pressure from hydrops
In Meniere's disease, hearing loss begins at low frequencies (250–1000 Hz) because the apex of the cochlea — which encodes these frequencies — is the most mechanically compliant and least rigid part of the cochlear duct. When endolymphatic pressure increases from hydrops, the apical region is distended most, causing early damage to the apical inner and outer hair cells. This is the opposite of NIHL and presbyacusis (both affecting the basal cochlea and causing high-frequency loss). The characteristic low-frequency audiometric notch in early Meniere's disease, often with partial recovery between attacks, is pathognomonic.